Software Engineer I/II - Scientific Computing
Iambic Therapeutics, Inc4 days ago
Boston, MA, USAEntry Level / Mid Level
Base Salary
$129k - $190k/yr
Responsibilities
- Partner with computational chemists and machine learning researchers to translate research needs into practical software solutions.
- Build and maintain Python applications, libraries, APIs, and command-line tools.
- Develop reliable workflows for computational drug discovery workloads.
- Improve orchestration, monitoring, and recovery for workloads on AWS, Modal, and Lambda.
- Integrate scientific applications with shared data, compute, and model services.
- Troubleshoot issues, document tools, and help scientists use them effectively.
- Contribute to software design, testing, code review, deployment, and production support.
Requirements
- Bachelor's degree in a relevant technical field and five or more years of software development experience, or equivalent practical experience.
- Strong Python skills and experience writing clear, tested, maintainable production code.
- Experience running scientific or batch workloads on AWS.
- Experience with Prefect or another workflow orchestration system.
- Familiarity with computational chemistry workloads such as molecular dynamics or docking.
- Familiarity with the machine learning model lifecycle.
- Strong service mindset, clear communication, and interest in helping scientists be effective.
Benefits
- Full-time role ideally based in Boston, with remote work elsewhere in the United States considered.
- Company-paid healthcare.
- Flexible spending accounts.
- Voluntary life insurance.
- 401(k) matching.
- Uncapped vacation.
- Access to an onsite gym and dining at Iambic's San Diego facility.
About Iambic Therapeutics, Inc
Iambic Therapeutics is a clinical-stage biotech that uses an AI-driven discovery platform to design and advance small-molecule medicines across multiple target classes. The company develops an internal, disease-agnostic pipeline and runs partnered programs, moving candidates from hit identification through IND and clinical trials. Founded in 2020 and headquartered in San Diego, it is privately held and completed a Series B round in 2024.